Dr. Daswani is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3300 E South St
Ste 110
Lakewood, CA 90805Phone+1 562-630-7279Fax+1 562-630-8828
Education & Training
Cedars-Sinai Medical CenterFellowship, Nephrology, 2004 - 2006- Cedars-Sinai Medical CenterResidency, Internal Medicine, 2001 - 2004
Albert Einstein College of MedicineClass of 2001
Certifications & Licensure
CA State Medical License 2003 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Nephrology
Clinical Trials
- A Phase 3 Study Comparing the Effects of Intravenous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin Start of enrollment: 2012 Jan 31
- Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease Start of enrollment: 2012 Jul 30
- Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D) Start of enrollment: 2016 Sep 28
Publications & Presentations
PubMed
- 31 citationsGraft survival following living-donor renal transplantation: a comparison of tacrolimus and cyclosporine microemulsion with mycophenolate mofetil and steroids.Suphamai Bunnapradist, Adarsh Daswani, Steven K. Takemoto
Transplantation. 2003-07-15 - 3 citationsPatterns of administration of antibody induction therapy and their associated outcomes.Suphamai Bunnapradist, Adarsh Daswani, Steven K. Takemoto
Clinical Transplants. 2002-01-01
Professional Memberships
- Member
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
